Loading
Combining a BRAF inhibitor with a MEK inhibitor shrank tumours in about two thirds of previously treated patients with BRAF V600E-mutant lung cancer, far more than BRAF inhibition alone, leading to the first approval for this driver.
Phase 2 multicohort study; this cohort treated 57 patients with previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer with dabrafenib plus trametinib.
Objective response was 63.2 percent with a median progression-free survival of 9.7 months, compared with 33 percent for dabrafenib alone in an earlier cohort; pyrexia, nausea and fatigue were common.
BRAF V600E is a routinely tested lung cancer driver, and BRAF plus MEK inhibition is the standard targeted therapy for it.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib, The Lancet Oncology.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.